

Freedom of Information Request	FOI 22-217	27 th May 2022
--------------------------------	------------	---------------------------

Q1. Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:

Please find below the quantities dispensed in the Health Board's pharmacy for Rheumatology only for the period February to April 2022. Please note the Health Board is only able to supply information by quantity and not by the number of patients treated:

- **Abatacept [Orencia]**
- **Adalimumab [Humira]**
- **Adalimumab Biosimilars**
- **Apremilast [Otezla]**
- **Baricitinib [Olmiant]**
- **Certolizumab [Cimzia]**
- **Etanercept [Enbrel]**
- **Etanercept Biosimilars**
- **Filgotinib [Jyseleca]**
- **Golimumab [Simponi]**
- **Guselkumab [Tremfya]**
- **Infliximab [Remicade]**
- **Infliximab Biosimilars**
- **Ixekizumab [Taltz]**
- **Risankizumab [Skyrizi]**
- **Rituximab [MabThera]**
- **Rituximab Biosimilars**
- **Sarilumab [Kevzara]**
- **Secukinumab [Cosentyx]**
- **Tocilizumab [Ro Actemra]**
- **Tofacitinib [Xeljanz]**
- **Upadacitinib [Rinvoq]**
- **Ustekinumab [Stelara]**

Type	Qty
ABATACEPT (ORENCIA CLICKJECT) 125 mg in 1mL Pre-Filled Pen 4 Pre-Filled Pen Pack	17
ABATACEPT (ORENCIA) 125 mg in 1mL Pre-Filled Syringe 4 Pre-Filled Syringe Pack	29
ABATACEPT 250 mg Intravenous Infusion 1 Vial Pack	2
ADALIMUMAB (HUMIRA) 40 mg in 0.4mL Pre-Filled Pen 2 Pre-Filled Pen Pack	104
ADALIMUMAB (HUMIRA) 40 mg in 0.4mL Pre-Filled Syringe 2 Pre-Filled Syringe Pack	29
ADALIMUMAB (IMRALDI) 40 mg in 0.8mL Pre-Filled Pen 2 Pre-Filled Pen Pack	198
CERTOLIZUMAB PEGOL (CIMZIA) 200 mg in 1mL Pre-Filled Pen 2 Pre-Filled Pen Pack	83
CERTOLIZUMAB PEGOL (CIMZIA) 200 mg in 1mL Pre-Filled Syringe 2 Pre-Filled Syringe Pack	125
ETANERCEPT (BENEPALI) 50 mg in 1mL Pre-Filled Pen 4 Pre-Filled Pen Pack	261

ETANERCEPT (BENEPALI) 50 mg in 1mL Pre-Filled Syringe 4 Pre-Filled Syringe Pack	22
ETANERCEPT (ENBREL) 25 mg in 0.5mL Pre-Filled Syringe 4 Pre-Filled Syringe Pack	8
ETANERCEPT (ENBREL) 50 mg in 1mL Pre-Filled Pen 4 Pre-Filled Pen Pack	26
ETANERCEPT (ENBREL) 50 mg in 1mL Pre-Filled Syringe 4 Pre-Filled Syringe Pack	7
GOLIMUMAB (SIMPONI) 100 mg in 1mL Pre-Filled Pen 1 Pre-Filled Pen Pack	8
GOLIMUMAB (SIMPONI) 50 mg in 0.5mL Pre-Filled Pen 1 Pre-Filled Pen Pack	46
GOLIMUMAB (SIMPONI) 50 mg in 0.5mL Pre-Filled Syringe 1 Pre-Filled Syringe Pack	4
INFLIXIMAB (INFLECTRA) 100 mg Intravenous Infusion 1 Vial Pack	14
INFLIXIMAB (REMICADE) 100 mg Intravenous Infusion 1 Vial Pack	10
IXEKIZUMAB (TALTZ) 80 mg in 1mL Pre-Filled Pen 1 Pre-Filled Pen Pack	34
RITUXIMAB (RIXATHON) 500 mg in 50mL Intravenous Infusion 1 Vial Pack	50
RITUXIMAB (TRUXIMA) 500 mg in 50mL Intravenous Infusion 1 Vial Pack	2
SARILUMAB (KEVZARA) 200 mg in 1.14mL Pre-Filled Pen 2 Pre-Filled Pen Pack	24
SARILUMAB (KEVZARA) 200 mg in 1.14mL Pre-Filled Syringe 2 Pre-Filled Syringe Pack	2
SECUKINUMAB 150 mg in 1mL Pre-Filled Pen 2 Pre-Filled Pen Pack	58
SECUKINUMAB 150 mg in 1mL Pre-Filled Syringe 2 Pre-Filled Syringe Pack	3
SECUKINUMAB 300 mg in 2mL Pre-Filled Pen 1 Pre-Filled Pen Pack	4
TOCILIZUMAB 162 mg in 0.9mL Pre-Filled Pen 4 Pre-Filled Pen Pack	52
TOCILIZUMAB 162 mg in 0.9mL Pre-Filled Syringe 4 Pre-Filled Syringe Pack	77
TOCILIZUMAB 200 mg in 10mL Intravenous Infusion 1 Vial Pack	6
TOCILIZUMAB 400 mg in 20mL Intravenous Infusion 1 Vial Pack	16
TOCILIZUMAB 80 mg in 4mL Intravenous Infusion 1 Vial Pack	23
TOFACITINIB 5 mg Tablets 56 Tablet Pack	15
USTEKINUMAB 45 mg in 0.5mL Pre-Filled Syringe 1 Pre-Filled Syringe Pack	12
USTEKINUMAB 90 mg in 1mL Pre-Filled Syringe 1 Pre-Filled Syringe Pack	4

Q2. Could you please provide the numbers of patients treated for Axial Spondyloarthritis ONLY in the last 3 months with the following drugs:

- **Adalimumab [Humira]**
- **Adalimumab Biosimilars**
- **Certolizumab [Cimzia]**
- **Etanercept [Enbrel]**
- **Etanercept Biosimilars**
- **Golimumab [Simponi]**
- **Infliximab [Remicade]**
- **Infliximab Biosimilars**
- **Ixekizumab [Taltz]**
- **Secukinumab [Cosentyx]**
- **Upadacitinib [Rinvoq]**

The Health Board does not record this information centrally and would have to review every patient record to determine this. Therefore, in order to comply with your request, the Health Board has established that this would exceed the appropriate costs limit under Section 12 of the Freedom of Information Act 2000 which is currently £450. As you will be aware this is not an exemption which requires us to consider the application of the public interest test. We have calculated that it would take in excess of 18 hours to review the record of each patient.